Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA?
NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through January 8, 2026. Shareholders who lost money on AQST stock may find out if you qualify for a free case evaluation or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Read more at prnewswire.com